Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Moderate Buy” from Brokerages

by · The Cerbat Gem

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have been given an average rating of “Moderate Buy” by the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $8.1667.

JSPR has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, Piper Sandler started coverage on Jasper Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price target for the company.

Get Our Latest Stock Analysis on JSPR

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR opened at $0.63 on Friday. The business’s 50-day moving average is $0.71 and its 200 day moving average is $0.79. Jasper Therapeutics has a 1 year low of $0.32 and a 1 year high of $2.69. The firm has a market capitalization of $21.10 million, a P/E ratio of -0.40 and a beta of 3.04.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. On average, analysts expect that Jasper Therapeutics will post -1.14 EPS for the current year.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity.

Recommended Stories